ResMed
731 hedge funds and large institutions have $19.7B invested in ResMed in 2022 Q4 according to their latest regulatory filings, with 115 funds opening new positions, 236 increasing their positions, 244 reducing their positions, and 35 closing their positions.
229% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 35
65% more call options, than puts
Call options by funds: $50.6M | Put options by funds: $30.6M
10% more funds holding
Funds holding: 667 → 731 (+64)
0.68% less ownership
Funds ownership: 65.78% → 65.1% (-0.68%)
3% less repeat investments, than reductions
Existing positions increased: 236 | Existing positions reduced: 244
6% less capital invested
Capital invested by funds: $21.1B → $19.7B (-$1.32B)
27% less funds holding in top 10
Funds holding in top 10: 15 → 11 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$50.2M |
| 3 |
N
Natixis
Paris,
France
|
+$46.4M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$45.6M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$40.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM Investment Management
Laguna Beach,
California
|
-$436M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$105M |
| 3 |
Millennium Management
New York
|
-$80.7M |
| 4 |
ZIG
Zurich Insurance Group
Zurich,
Switzerland
|
-$53.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$40.3M |
RMD Hedge Fund Activity: Q4 2022 in Review
731 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q4 2022, worth a combined $19.7B — down 6.3% from $21.1B a quarter earlier.
Buyers outnumbered sellers: 115 funds opened new RMD positions and 35 closed out — a net gain of 80 holders — while 236 added to existing stakes and 244 trimmed.
The largest buyer was Vanguard Group, adding an estimated $53.6M. The largest seller was WCM Investment Management, cutting an estimated $436M.
- 731 institutional investors held ResMed (RMD) as of Q4 2022, up from 667 in Q3 2022.
- Funds reported $19.7B of ResMed stock for Q4 2022, down 6.3% quarter-over-quarter.
- 115 funds opened new ResMed positions in Q4 2022 and 35 closed out, a net change of +80 holders.
- The largest ResMed buyer in Q4 2022 was Vanguard Group, an estimated $53.6M added.
- The largest ResMed seller in Q4 2022 was WCM Investment Management, an estimated $436M sold.
Based on aggregated 13F filings for Q4 2022.